
First allogeneic cancer immunotherapy hits market
On December 20th, the European Commission approved Tabelecleucel (EbvalloTM) as a monotherapy for the treatment of adult and paediatric patients who...

Germany’s Curevac offers common shares
In addition to these ordinary shares, Tübingen-based CureVac is enticing investors to give up another 15% of the number of ordinary shares under the...

Evidence of deliberate climate damage
For decades, some members of the fossil fuel industry tried to convince the public that a causative link between fossil fuel use and climate warming...

First hints for leukopenia diagnostic in MS
Disease-modifying therapies for multiple sclerosis (MS) may positively influence the composition of the intestinal flora. At least this is what a...

Chong Kun Dang Pharm licences Synaffix ADC platform
Though the companies did not give any financial details, former licencing deals of Synaffix to global pharma companies such as Amgen or ranged...

Ethris inks €15m deal with Indian Ciplas
The investment is aimed at establishing a long-term strategic partnership until the end of Q1/2023 between Cipla and Ethris for the development of...

Neurodegenerative disorders are being fought with €28m
The Danish biotech Teitur Trophics ApS, aiming to treat chronic neurological disorders, has completed a €28m Series A funding. With the money, Teitur...